GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Comera Life Sciences Holdings Inc (OTCPK:CMRA) » Definitions » Net Margin %

Comera Life Sciences Holdings (Comera Life Sciences Holdings) Net Margin % : -1,583.82% (As of Sep. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Comera Life Sciences Holdings Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Comera Life Sciences Holdings's Net Income for the three months ended in Sep. 2023 was $-2.15 Mil. Comera Life Sciences Holdings's Revenue for the three months ended in Sep. 2023 was $0.14 Mil. Therefore, Comera Life Sciences Holdings's net margin for the quarter that ended in Sep. 2023 was -1,583.82%.

The historical rank and industry rank for Comera Life Sciences Holdings's Net Margin % or its related term are showing as below:

CMRA' s Net Margin % Range Over the Past 10 Years
Min: -2844.23   Med: -1703.75   Max: -479.68
Current: -901


CMRA's Net Margin % is ranked worse than
72.87% of 1021 companies
in the Biotechnology industry
Industry Median: -148.41 vs CMRA: -901.00

Comera Life Sciences Holdings Net Margin % Historical Data

The historical data trend for Comera Life Sciences Holdings's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Comera Life Sciences Holdings Net Margin % Chart

Comera Life Sciences Holdings Annual Data
Trend Dec20 Dec21 Dec22
Net Margin %
-479.68 -1,703.75 -2,844.23

Comera Life Sciences Holdings Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -1,309.36 -1,899.36 -631.30 -448.25 -1,583.82

Competitive Comparison of Comera Life Sciences Holdings's Net Margin %

For the Biotechnology subindustry, Comera Life Sciences Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Comera Life Sciences Holdings's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Comera Life Sciences Holdings's Net Margin % distribution charts can be found below:

* The bar in red indicates where Comera Life Sciences Holdings's Net Margin % falls into.



Comera Life Sciences Holdings Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Comera Life Sciences Holdings's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin=Net Income (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-18.004/0.633
=-2,844.23 %

Comera Life Sciences Holdings's Net Margin for the quarter that ended in Sep. 2023 is calculated as

Net Margin=Net Income (Q: Sep. 2023 )/Revenue (Q: Sep. 2023 )
=-2.154/0.136
=-1,583.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Comera Life Sciences Holdings  (OTCPK:CMRA) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Comera Life Sciences Holdings Net Margin % Related Terms

Thank you for viewing the detailed overview of Comera Life Sciences Holdings's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Comera Life Sciences Holdings (Comera Life Sciences Holdings) Business Description

Traded in Other Exchanges
N/A
Address
12 Gill Street, Suite 4650, Woburn, MA, USA, 01801
Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera's internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company's partners' biologic medicines to deliver enhanced formulations that facilitate self-injectable care.
Executives
Michael Gerard Campbell officer: Chief Financial Officer C/O COMERA LIFE SCIENCES HOLDINGS, INC., 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Charles Cherington 10 percent owner ONE BOW STREET, CAMBRIDGE MA 02138
David Soane 10 percent owner C/O SOANE LABS, LLC, 380 NE 72ND TERRACE, MIAMI FL 33138
Robert Patrick Mahoney officer: Chief Scientific Officer 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Barbara K Finck director C/O PROTINE DESIGN LAB, 3858 JACKSON ST, SAN FRANCISCO CA 94118
Kirsten Flowers director C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
James Sherblom director 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Stuart A Randle director 585 WEST 500 SOUTH, BOUNTIFUL UT 84010
Sullivan Edward Aloysius Jr. director 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Sirshendu Roopom Banerjee director 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Janice Mccourt officer: Chief Business Officer C/O COMERA LIFE SCIENCES HOLDINGS, INC., 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Jeffrey S. Hackman director, officer: See Remarks 12 GILL STREET, SUITE 4650, WOBURN MA 01801
John D. Yee director 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Neal Muni officer: See Remarks 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Phoenix Venture Partners Lp 10 percent owner 36 DOCKSIDE CIRCLE, REDWOOD SHORES CA 94065